Glucokinase - Pipeline Review, H2 2020
Glucokinase - Pipeline Review, H2 2020
SUMMARY
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase - Pipeline Review, H2 2020, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Infectious Disease which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Coronavirus Disease 2019 (COVID-19), Diabetes and Obesity.
Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase - Pipeline Review, H2 2020, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Infectious Disease which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Coronavirus Disease 2019 (COVID-19), Diabetes and Obesity.
Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
- The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Eli Lilly and Co
Hua Medicine Shanghai Ltd
Impetis Biosciences Ltd
Kriya Therapeutics Inc
Ligand Pharmaceuticals Inc
Merck & Co Inc
Pfizer Inc
Sanwa Kagaku Kenkyusho Co Ltd
vTv Therapeutics Inc
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles
AZD-1656 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dorzagliatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTA-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2608204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04937319 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTP-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones
Featured News & Press Releases
Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin
Sep 16, 2020: vTv Therapeutics to present additional positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting
Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combination trial of dorzagliatin
Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin’s phase III Monotherapy trial
Jun 15, 2020: Hua Medicine’s Dorzagliatin demonstrates improvements in ?-Cell function in data presented at the American Diabetes Association’s 80th Scientific Sessions
Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association’s Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients
May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index
May 27, 2020: vTv Therapeutics to present full clinical study results from the positive phase 2 simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions
Apr 27, 2020: Hua Medicine announces positive results of the combination study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
Feb 13, 2020: Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer
Feb 10, 2020: vTv Therapeutics announces positive results from part 2 of the Phase 2 Simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes
Feb 07, 2020: vTv Therapeutics to host investor call and announce results from part 2 of the phase 2 Simplici-T1 Study of TTP399 - potential first-in-class oral adjunctive therapy for patients with Type 1 Diabetes
Jan 06, 2020: Hua Medicine announces positive results of HMM0110 and HMM0111
Nov 25, 2019: Hua Medicine’s global first-in-class drug was presented at 2019 Scientific Meeting of CDS
Nov 11, 2019: Hua Medicine’s pivotal phase III monotherapy trial of dorzagliatin, a dual-acting glucokinase modulator, achieves primary efficacy endpoint in patients with type 2 diabetes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Eli Lilly and Co
Hua Medicine Shanghai Ltd
Impetis Biosciences Ltd
Kriya Therapeutics Inc
Ligand Pharmaceuticals Inc
Merck & Co Inc
Pfizer Inc
Sanwa Kagaku Kenkyusho Co Ltd
vTv Therapeutics Inc
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles
AZD-1656 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dorzagliatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTA-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2608204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04937319 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTP-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones
Featured News & Press Releases
Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin
Sep 16, 2020: vTv Therapeutics to present additional positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting
Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combination trial of dorzagliatin
Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin’s phase III Monotherapy trial
Jun 15, 2020: Hua Medicine’s Dorzagliatin demonstrates improvements in ?-Cell function in data presented at the American Diabetes Association’s 80th Scientific Sessions
Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association’s Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients
May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index
May 27, 2020: vTv Therapeutics to present full clinical study results from the positive phase 2 simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions
Apr 27, 2020: Hua Medicine announces positive results of the combination study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
Feb 13, 2020: Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer
Feb 10, 2020: vTv Therapeutics announces positive results from part 2 of the Phase 2 Simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes
Feb 07, 2020: vTv Therapeutics to host investor call and announce results from part 2 of the phase 2 Simplici-T1 Study of TTP399 - potential first-in-class oral adjunctive therapy for patients with Type 1 Diabetes
Jan 06, 2020: Hua Medicine announces positive results of HMM0110 and HMM0111
Nov 25, 2019: Hua Medicine’s global first-in-class drug was presented at 2019 Scientific Meeting of CDS
Nov 11, 2019: Hua Medicine’s pivotal phase III monotherapy trial of dorzagliatin, a dual-acting glucokinase modulator, achieves primary efficacy endpoint in patients with type 2 diabetes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Hua Medicine Shanghai Ltd, H2 2020
Pipeline by Impetis Biosciences Ltd, H2 2020
Pipeline by Kriya Therapeutics Inc, H2 2020
Pipeline by Ligand Pharmaceuticals Inc, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2020
Pipeline by vTv Therapeutics Inc, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Hua Medicine Shanghai Ltd, H2 2020
Pipeline by Impetis Biosciences Ltd, H2 2020
Pipeline by Kriya Therapeutics Inc, H2 2020
Pipeline by Ligand Pharmaceuticals Inc, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2020
Pipeline by vTv Therapeutics Inc, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
